ÀÇ·á¿ë ·Îº¿ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 154¾ï 7,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£(2025-2030³â) µ¿¾È 16.13%ÀÇ CAGR·Î 2030³â¿¡´Â 326¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Áö³ ¸î ³â µ¿¾È ³ëÀÎ ½Ã¼³¿¡¼ ÀÇ·á¿ë ·Îº¿¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ½Ç¼ö·Î ÀÎÇÑ ³«»óÀ¸·Î ÀÎÇÑ ÀÀ±Þ½Ç ¹æ¹® Ƚ¼ö¸¦ ÁÙÀ̰í, ÀçÅà °£È£ÀÇ Á¢±Ù¼º°ú °æÁ¦¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â Áß¿äÇÑ ³ë·Â Áß Çϳª´Â ·Îº¿ °£È£ÀÇ µµÀÔÀÔ´Ï´Ù.
°í·ÉÀÚÀÇ ¼ö¼ú °Ç¼ö Áõ°¡¿Í ¿Ü»ó »ç·Ê Áõ°¡·Î ÀÎÇØ Á¤È®Çϰí ÀûÀýÇÑ º¹°°æ ¼ö¼ú ¹× ÀÇ·á ½Ã¼ú ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ¼ö¼ú ºÐ¾ß Àü¹Ý¿¡ °ÉÃÄ ÃÖ¼Òħ½À ¼ö¼úÀÇ ±âȸ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ·Îº¿ º¸Á¶ ¼ö¼úÀÌ ºü¸£°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ·Îº¿ ¼ö¼úÀÇ »ó¾÷Àû Ȱ¿ëÀÌ 10³âÀÌ °¡±î¿öÁü¿¡ µû¶ó ½ÃÀåÀÌ ´Ù¾çÇØÁö°í, »õ·Î¿î ±â¼úÀ» ÅëÇØ ºñ¿ë Àý°¨°ú ¼ÒÇüȸ¦ ½ÇÇöÇÑ »õ·Î¿î ¼ö¼ú ¹æ¹ýÀÌ µîÀåÇϰí ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, ÀÇ·á¿ë ·Îº¿Àº ÁßÀç ¹× Áø´Ü ¸ñÀûÀ¸·Îµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù ¸î ³â µ¿¾È ·Îº¿ °øÇÐ ¹× ÀÚµ¿È ¼Ö·ç¼ÇÀÇ Àû¿ë ºÐ¾ß´Â ÀÇ·á/Á¦¾à ½ÇÇè½Ç·Î È®´ëµÇ°í ÀÖÀ¸¸ç, ¼öÀÛ¾÷, ¹Ýº¹ ÀÛ¾÷ ¹× ´ë·® ÀÛ¾÷À» ÀÚµ¿ÈÇÏ¿© °úÇÐÀÚ¿Í ±â¼úÀÚ°¡ º¸´Ù Àü·«ÀûÀÎ ÀÛ¾÷¿¡ ÁýÁßÇÏ°í ´õ »¡¸® ¹ß°ßÀ» ½ÇÇöÇÒ ¼ö ÀÖµµ·Ï ·Îº¿ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
Á÷°üÀûÀÎ ¼ö¼úÀÌ ·Îº¿ ¼ö¼ú ½ÃÀåÀ» µ¶Á¡ÇÏ°í »ó´çÇÑ ½ÃÀå Á¡À¯À²À» À¯ÁöÇØ ¿Â ±â°£µµ ±æ¾ú½À´Ï´Ù. ´ÙºóÄ¡ÀÇ Æ¯Çã°¡ ¸¸·áµÇ°í ÀÚµ¿ ½Ã½ºÅÛ °³¹ßÀÌ ºñ¾àÀûÀ¸·Î Áõ°¡ÇÏ´Â ´Ü°è¿¡ ÀÖ½À´Ï´Ù. »õ·Î¿î ½Ã½ºÅÛÀº ½Å±â¼ú, ºñ¿ë Àý°¨, ¼ÒÇüȶó´Â ¼¼ °¡Áö ÁÖ¿ä ¼ö´ÜÀ» ÅëÇØ ´ÙºóÄ¡ ¸ðµ¨À» °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ¹Ì±¹°ú À¯·´ÀÇ º´¿ø¿¡¼´Â ´Ù¾çÇÑ Áúº´À» Ä¡·áÇϱâ À§ÇØ ·Îº¿ ¼ö¼úÀÌ ºü¸£°Ô äÅõǰí ÀÖ½À´Ï´Ù. °¡Àå ³Î¸® »ç¿ëµÇ´Â ÀÓ»ó¿ë ·Îº¿ ¼ö¼ú ½Ã½ºÅÛ Áß Çϳª´Â ¼ö¼ú±â±¸°¡ ÀåÂøµÈ ±â°è½Ä ¾Ï°ú Ä«¸Þ¶ó ¾ÏÀÔ´Ï´Ù. ·Îº¿ º¸Á¶ ¼ö¼úÀÇ ¿¹·Î´Â »ý°Ë, ¾Ï Á¾¾ç Á¦°Å, ½ÉÀåÆÇ¸· º¹¿ø, À§ ¿ìȸ¼ú µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ ÀåÁ¡¿¡µµ ºÒ±¸Çϰí, ³ôÀº µµÀÔ ºñ¿ë, ƯÈ÷ ½ÅÈï±¹ ½ÃÀå¿¡¼ÀÇ ³·Àº ÀÎÁöµµ, ·Îº¿ ÀÇ·á ½Ã½ºÅÛÀ» Á¶ÀÛÇÒ ¼ö ÀÖ´Â ±â¼úÀû Àü¹® Áö½ÄÀÇ ºÎÁ· µîÀÌ Á¶»ç ´ë»ó ½ÃÀåÀÇ ¼ºÀåÀ» °¡·Î¸·°í ÀÖ´Â Å« °úÁ¦ÀÔ´Ï´Ù.
COVID-19°¡ ¿Ü°úÀǻ翡°Ô °¡Á®¿À´Â ½É°¢ÇÑ À§ÇèÀ¸·Î ÀÎÇØ ¿©·¯ ¿Ü°ú ÇÐȸ´Â ÇöÀç À¯Çິ¿¡¼ ÀÌ·¯ÇÑ ½Ã¼ú¿¡ ´ëÇÑ ¾ÈÀü ±Ç°í¾ÈÀ» ¸¶·ÃÇß½À´Ï´Ù. ·Îº¿Àº °¢ ¼ö¼ú ȯÀÚ°¡ ÀÔ¿øÇÏ´Â µ¿¾È Åë°úÇÏ´Â ÀÏ·ÃÀÇ È帧ÀÇ ´Ù¾çÇÑ ºÎºÐ¿¡ ÅëÇÕµÇ¾î º´¿ø±ÕÀÇ È®»êÀ» ¼º°øÀûÀ¸·Î ¹æÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ÆÒµ¥¹ÍÀÌ °¡Á®¿Â Å« ¿µÇâ°ú ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÌ Á¦°øÇÏ´Â ÀÌÁ¡À¸·Î ÀÎÇØ ·Îº¿ ÀÇ·á ½Ã½ºÅÛÀÇ Ã¤ÅÃÀº ¿¹Ãø ±â°£ µ¿¾È ´õ¿í È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
·Îº¿ ¼ö¼úÀº ·Îº¿ °øÇÐÀ» ÀÌ¿ëÇÏ¿© ¿Ü°úÀû ½Ã¼úÀ» ½ÃÇàÇÏ´Â ÃÖ¼Òħ½À ¼ö¼úÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ·Îº¿ ½Ã½ºÅÛÀº ¿Ü°úÀǻ簡 Á¶ÀÛÇÏ°í ·Îº¿ ÆÈ¿¡ ÀåÂøµÈ ¼ÒÇüÈµÈ ¼ö¼ú µµ±¸·Î ±¸¼ºµÇ¾î ÀÖ¾î ¿Ü°úÀǻ簡 Á¤È®ÇÏ°Ô ¼ö¼úÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼ö¼ú¿ë ·Îº¿ ºÎ¹®À» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ÀÇ·á ÀÚµ¿È¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÷´Ü ·Îº¿ ¼ö¼ú¿¡ ´ëÇÑ Ãß¼¼ÀÔ´Ï´Ù. ¿îµ¿ ÀúÇ×°ú Á¶Á÷ ÀúÇ׿¡ ´ëóÇϱâ À§ÇØ ¿¬±¸ °³¹ßÀº Çùµ¿ ·Îº¿À» äÅÃÇÑ »õ·Î¿î Àü·«À» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Çùµ¿ ·Îº¿Àº ¼¶¼¼ÇÑ ¼ö¼úÀ̳ª ¹«±Õ ȯ°æ¿¡¼ ÀÎü ¿À¿° °¡´É¼ºÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
¼ö¼ú¿ë ·Îº¿ ºÎ¹®Àº ÀÇ·á¿ë ·Îº¿¿¡¼ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â Tier-1 º´¿øÀÇ ·Îº¿ ¼ö¼ú ½Ã½ºÅÛ µµÀÔ Áõ°¡, °íÈ¿À² ¹× ±³Ã¼ °¡´ÉÇÑ ºÎǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Àü ¼¼°èÀûÀ¸·Î ½ÃÇàµÇ´Â ·Îº¿ ¼ö¼ú °Ç¼ö Áõ°¡, ¼ö¼ú¸¶´Ù ¹Ýº¹ÀûÀ¸·Î ¿ä±¸µÇ´Â ±â±¸ ¹× ¾×¼¼¼¸®¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.
·Îº¿ ¼ö¼úÀÌ ±âÁ¸ÀÇ º¹°°æ ¹× Èä°°æ ¼ö¼úÀÇ ´ÜÁ¡À» È¿°úÀûÀ¸·Î ÇØ°áÇÏ°í º¹ÀâÇÑ Ã·´Ü ¼ö¼úÀ» º¸´Ù ³ôÀº Á¤È®µµ¿Í ÃÖ¼Òħ½ÀÀ¸·Î ¿Ï·áÇÒ ¼ö ÀÖ°Ô µÈ °Íµµ ¼ö¼ú ·Îº¿ÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÷´Ü ÀÇ·á±â±â¿¡ ´ëÇÑ ÅõÀÚ È®´ëµµ ¿¬±¸ ´ë»ó ½ÃÀåÀÇ ¼ºÀå¿¡ À¯¸®ÇÑ Àü¸ÁÀ» ³º°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ÅõÀÚÀºÇà Mediobanca¿¡ µû¸£¸é ÀÇ·á±â±â »ê¾÷ÀÇ ¸ÅÃâÀº 2017³â 3,760¾ï À¯·Î(¾à 4,020¾ï ´Þ·¯)¿¡¼ 2024³â 5,210¾ï À¯·Î(¾à 5,570¾ï ´Þ·¯)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ, ¼ö¼ú¿ë ·Îº¿¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ºñ¸¸ ¼ö¼ú, Çï·¯±Ù ÀýÁ¦¼ú, À§ ÀýÁ¦¼ú, Å»Àå ¼ö¼ú, ´ã³¶ ÀýÁ¦¼ú, °æ±¸ ¼ö¼ú, ÃéÀå ÀýÁ¦¼ú µî ´Ù¾çÇÑ ¼ö¼ú¿¡¼ ¼ö¼ú ·Îº¿ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, Àü ¼¼°èÀûÀ¸·Î ÀÏ¹Ý ¿Ü°ú ¼ö¼úÀÇ ½ÃÇà °Ç¼ö°¡ Áõ°¡Çϰí ÀÖ´Â µ¥ ±âÀÎÇÕ´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ã·´Ü ÀÇ·á ÀÎÇÁ¶ó ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä´Â ¿¹Ãø ±â°£ µ¿¾È °ÇÀüÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÇ·á¿ë ·Îº¿ ½ÃÀåÀÇ ÀáÀç·ÂÀº ºü¸£°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. °¢±¹ Á¤ºÎ´Â ÀÇ·á ¹× Á¦¾à ºÎ¹®¿¡¼ ±â¼úÀû µ¹ÆÄ±¸¸¦ ¸ð»öÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå È®´ë¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ´Â ÀÇ·á¿ë ·Îº¿¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë, Ãß°¡ ¹ßÀü, ÇâÈÄ ¸î ³â µ¿¾È ´ë±Ô¸ð ÅõÀÚÀÇ ¹®À» ¿¾îÁÙ °ÍÀÔ´Ï´Ù.
ÀÌ Áö¿ª¿¡¼´Â Áß±¹ÀÌ ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. Áß±¹ÀÇ ÀÇ·á¿ë ·Îº¿¿¡ ´ëÇÑ ¼ö¿ä´Â ÁÖ·Î ±â±â ±â¹Ý ¼ºñ½ºÀÇ Ã¤Åà Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¼÷·ÃµÈ ¹°¸®Ä¡·á»ç ¹× °£º´ÀÎ ºÎÁ·°ú °°Àº ´Ù¸¥ ¿äÀε鵵 ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
South China Morning¿¡ µû¸£¸é, ´ÙºóÄ¡ ½Ã½ºÅÛÀº ÇöÀç±îÁö Áß±¹¿¡¼ 6¸¸ °Ç ÀÌ»óÀÇ ¼ö¼ú¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, Áß±¹ Á¤ºÎ´Â ¿Ü±¹ ±â¼ú¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãß±â À§ÇØ Áö³ ¸î ³â µ¿¾È ¼ö¼ú¿ë ·Îº¿À» Æ÷ÇÔÇÑ Áö´ÉÇü ·Îº¿ ¹× ·Îº¿ ÀÇ·á±â±â¸¦ °³¹ßÇÏ´Â 30°³ ÀÇ·á±â±â Á¦Á¶¾÷ü¸¦ Áö¿øÇß½À´Ï´Ù. ÇÏ´Â 30°³ ÀÌ»óÀÇ ÀÇ·á±â±â Á¦Á¶¾÷ü¸¦ Áö¿øÇؿԽÀ´Ï´Ù.
ÀÌ·¯ÇÑ Ãß¼¼´Â ÀÇ·á±â±â Á¦Á¶¾÷üµéÀÌ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» °³¹ßÇϱâ À§ÇÑ ¿¬±¸ °³¹ß ³ë·ÂÀ» ´õ¿í °ÈÇÏ´Â °ÍÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 9¿ù »óÇÏÀÌÀÇ ÇÑ ·Îº¿ ±â¾÷Àº Àǻ簡 Á¼Àº °ø°£¿¡¼ º¹ÀâÇÑ ¼ö¼úÀ» ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÖ´Â 4°³ÀÇ ÆÈÀ» °¡Áø º¹°°æ ¼ö¼ú ·Îº¿À» °³¹ßÇß½À´Ï´Ù.
¶ÇÇÑ, ÇýÁÖÀÇ ZhongkaiHi-Tech Zone¿¡¼ SS Innovations´Â º¹ÀâÇÑ µ¿ÀÛ Á¦¾î°¡ °¡´ÉÇÑ Àú·ÅÇÑ °¡°ÝÀÇ ¸ðµâÇü ·Îº¿ ¼ö¼ú ½Ã½ºÅÛÀ» °³¹ß ¹× Å×½ºÆ®Çϰí ÀÖ½À´Ï´Ù. ÀÌ È¸»ç´Â Áß±¹ Á¤ºÎ·ÎºÎÅÍ ¾à 1,500¸¸ ´Þ·¯ÀÇ ¿¹»êÀ» Áö¿ø¹Þ¾Æ Àü ¼¼°è ÀÎÀ縦 ä¿ëÇϰí À°¼ºÇϰí ÀÖ½À´Ï´Ù.
È£ÁÖ¿¡¼´Â ¾à 20³â ÀüºÎÅÍ ·Îº¿À» ÀÌ¿ëÇÑ ÃÖ¼Òħ½À¼ö¼ú(MAS)ÀÌ ½ÃÇàµÇ¾î ¿Ô±â ¶§¹®¿¡ È£ÁÖÀÇ ÀÇ·á¿ë ·Îº¿ ºÐ¾ß´Â ¸Å¿ì Á¤±³ÇÑ ¼öÁØÀÔ´Ï´Ù. ±âÁ¸ ¼ö¼ú ·Îº¿À» »ç¿ëÇÏ´Â ¿Ü°úÀÇ»çÀÇ À°Ã¼Àû ºÎ´ãÀ» ÁÙÀ̱â À§ÇØ ¼³°èµÈ ¼ö¼ú ·Îº¿ Versius°¡ Ãֱ٠ȣÁÖ¿¡ µµÀÔµÇ¾î ¼¼°è ÀÇ·á ·Îº¿ »ê¾÷¿¡¼ È£ÁÖÀÇ À§»óÀ» ÀÔÁõÇϰí È®º¸Çß½À´Ï´Ù.
ÀÇ·á¿ë ·Îº¿ ½Ã½ºÅÛ ½ÃÀåÀº ¿©·¯ ¾÷ü°¡ Á¸ÀçÇÔ¿¡µµ ºÒ±¸Çϰí, ½ÃÀå ¼ö¿äÀÇ ´ëºÎºÐÀÌ ´ëÇü ¾÷üµéÀÇ Ã·´Ü Á¦Ç°¿¡ ÀÇÇØ ÃæÁ·µÇ°í Àֱ⠶§¹®¿¡ °æÀïÀÌ Ä¡¿ÇÕ´Ï´Ù. ¼ºÀå°ú °æÀïÀÇ ¹è°æ¿¡´Â ÀÇ·á °³¼±À» À§ÇÑ À¯·´ ¹× ¹Ì±¹°úÀÇ Á¦ÈÞ, ±¹³» Á¦Á¶¾÷üÀÇ ¼ö¼ú¿ë ·Îº¿ °³¹ß, ¿¬±¸°³¹ßÀ» ¸ñÀûÀ¸·Î ÇÑ Áö¿ª ´ëÇаúÀÇ ¿©·¯ Á¤ºÎ Á¦ÈÞ µîÀÌ ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷µéÀº ½ÃÀå Á¡À¯À²°ú ¼öÀͼºÀ» ³ôÀ̱â À§ÇØ Àü·«Àû °øµ¿ ÀÌ´Ï¼ÅÆ¼ºê¸¦ äÅÃÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷À¸·Î´Â Intuitive Surgical Inc., Auris Surgical Rbots Inc.
2023³â 4¿ù, Apollo Cancer Centres, Navi Mumbai´Â Á¾¾çÇÐ, ºñ´¢±â°ú, ´ëÀåÇ×¹®¿Ü°ú, ºÎÀΰú, ÈäºÎ, ½ÉÀåÇÐ, ¼Ò¾Æ°ú, ¼Òȱ⠿ܰú, ½ÅÀå À̽Ä, °£ ÀÌ½Ä ºÎ¹®¿¡¼ »ç¿ëÇÒ ¼ö ÀÖ´Â 4¼¼´ë ÷´Ü ´ÙºóÄ¡ Xi ·Îº¿ ½Ã½ºÅÛÀ» Ãâ½ÃÇÏ¿´½À´Ï´Ù.
2023³â 2¿ù, ¹³¹ÙÀÌ¿¡ À§Ä¡ÇÑ Global HospitalÀº ´ÙºóÄ¡ Xi ·Îº¿ ¼ö¼ú ½Ã½ºÅÛÀ» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ·Îº¿ ¼ö¼ú ½Ã½ºÅÛÀº ¿Ü°ú Àǻ簡 ÃÖ¼Òħ½À ¼ö¼úÀ» Á¤È®ÇÏ°í ¾ÈÀüÇÏ°Ô ¼öÇà ÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ Ã·´Ü ½Ã½ºÅÛÀº ºÎÀΰú, ºñ´¢±â°ú, Á¾¾çÇÐ, °£ À̽Ä, ½ÉÀå ¼ö¼ú, ÈäºÎ ¼ö¼ú, ¼Ò¾Æ ¼ö¼ú, ¼Òȱ⠼ö¼ú µî ´Ù¾çÇÑ ¼ö¼ú ºÐ¾ß¿¡¼ »ç¿ëµÇ¾î ȯÀÚÀÇ Ä¡·á °á°ú¿Í »îÀÇ ÁúÀ» Çâ»ó½Ã۰í ÀÖ´Ù°í ȸ»ç ÃøÀº ¹àÇû½À´Ï´Ù.
The Medical Robotic Systems Market size is estimated at USD 15.47 billion in 2025, and is expected to reach USD 32.67 billion by 2030, at a CAGR of 16.13% during the forecast period (2025-2030).
The public's perception of medical robots in senior living facilities has improved over the last few years. One of the key initiatives that could lower the number of ER visits brought on by accidental falls and increase the accessibility and affordability of at-home care is the implementation of robotic care.
With the rising number of surgical procedures in the geriatric population and mounting cases of trauma injuries, the demand for accurate and proper laparoscopic surgeries and medical procedure solutions has been increasing. As a result, robot-assisted surgery has quickly expanded due to growing opportunities for minimally invasive surgery across the surgical domains. As robotic surgery approaches a decade of commercial use, the market is diversifying, and novel surgical modalities with the new technology decreased costs, and smaller sizes are becoming available.
For instance, medical robots have also increased for intervention and diagnostic purposes. Recent years have also witnessed the application area of robotics and automation solutions extending to medical/pharmaceutical research laboratories, where they are increasingly being used to automate manual, repetitive, and high-volume tasks so scientists and technicians can focus their attention on more strategic tasks to ensure discoveries happen faster.
For a significant period, intuitive surgical procedures have dominated the robotic surgical market and maintained a considerable market share. With original da Vinci patents expiring, the stage is set for an exponential increase in automatic system development. The newer systems seek to improve the da Vinci model through three main avenues: novel technology, reduced cost, and size reduction.
Furthermore, US and European hospitals have rapidly adopted robotic surgery to treat various conditions. One of the most widely used clinical robotic surgical systems includes mechanical and camera arms with surgical instruments attached. Examples of robot-assisted procedures include biopsies, removal of cancerous tumors, repairing heart valves, and gastric bypasses.
Despite all these benefits, factors such as a higher adoption cost, a lower awareness, especially in developing regions, and a lack of technical expertise to operate robotic medical systems are among the significant factor challenging the growth of the studied market.
Due to the significant risk that COVID-19 poses to surgeons, various surgical associations developed safety recommendations for these procedures in the present pandemic. Robots can be included in different parts of the sequence that each surgical patient travels through during their hospital stay to successfully prevent the spread of pathogens. As a result of the greater exposure the pandemic has provided and the benefits these systems offer, the adoption of robotic medical systems is anticipated to grow further during the forecast period.
Robotic surgery is a minimally invasive surgery utilizing robotics for performing surgical procedures. These robotic systems are operated by surgeons and consist of miniaturized surgical instruments mounted on robotic arms, thus allowing surgeons to perform the surgeries precisely.
The key factors boosting the surgical robots segment are the increasing need for healthcare automation and the trend toward advanced robotic surgeries. To address motion and tissue resistance, researchers are developing new strategies with the adoption of collaborative robots. For instance, Collaborative robots assist in lowering the possibility of human contamination in delicate operations and sterile settings.
The surgical robotics segment accounted for a significant portion of medical robotics, owing to the rising adoption of robotic surgical systems across Tier-1 hospitals, demand for highly efficient replaceable components, increase in the volume of robotic procedures performed worldwide, and growing demand for instruments & accessories due to their recurring need per procedure.
Another major factor driving the adoption of surgical robots is that robotic surgeries have effectively solved the drawbacks of conventional laparoscopic and thoracoscopic surgery, enabling the completion of intricate and advanced surgical procedures with higher precision and a minimally intrusive method. Growing investment in advanced medical devices also creates a favorable outlook for the growth of the studied market. For instance, according to Mediobanca, an investment banking company, the revenue of the medical device industry is anticipated to grow from EUR 376 billion (~USD 402 billion) in 2017 to EUR 521 billion (~USD 557 billion) by 2024.
Furthermore, there is projected to be a major increase in the market's demand for surgical robots. This can be attributed to the increasing use of surgical robots in a variety of surgical procedures, including bariatric surgery, heller myotomy, gastrectomy, hernia repair, cholecystectomy, transoral surgery, and pancreatectomy, as well as an increase in the volume of general surgery procedures performed globally.
The demand for the advanced and innovative healthcare infrastructure system in APAC will witness healthy growth during the forecast period. Medical robotics' market potential in the APAC area is expanding quickly. Governments across various countries are also looking for technological breakthroughs in their medical and pharmaceutical sectors, which are also critical to market expansion. This opens the door for greater accessibility to medical robotics, additional advancements, and larger investment in the upcoming years.
China contributes a majority of its market share in the region. Chinese demand for medical robots is mainly driven by the increasing adoption of instrument-based services. The demand is also supported by other factors, such as the lack of skilled physiotherapists and caretakers.
According to the South China Morning, while the da Vinci system is broadly used in China in more than 60,000 operations to date, the Chinese government is eager to reduce its dependence on foreign technology; as a result, it has backed more than 30 MedTech manufacturers who develop intelligent robots and robotic medical devices, including surgical robots in the past few years.
Such trends are also encouraging medical device manufacturers further enhance their R&D efforts to develop innovative solutions. For instance, in September 2022, a Shanghai-based robotics enterprise developed a four-arm laparoscopic surgical robot to help doctors carry out complex surgeries in narrow spaces.
Furthermore, in the ZhongkaiHi-Tech zone in Huizhou, SS Innovations is developing and testing an affordable, modular robotic surgical system capable of complex motion control. The company is working with a budget of around USD 15 million from the Chinese government to recruit and train talent worldwide.
Because Australia has been using robotic-assisted minimal access surgery (MAS) for approximately 20 years, the Australian medical robotics sector is well-sophisticated. Versius, a surgical robot designed to reduce the heavy physical demand on surgeons using conventional surgical robots, was recently introduced in Australia, demonstrating and securing the nation's position in the worldwide medical robotics industry.
The Medical Robotic Systems Market is competitive as the majority of the market demand is satisfied by the advanced offerings from major players despite the presence of several players. The growth and competitiveness can be attributed to Western partnerships to improve healthcare, the developing of surgical robots by domestic manufacturers, and multiple government collaborations with regional universities for research and development purposes. These companies are adopting strategic collaborative initiatives to increase their market share and profitability. Some key market players include Intuitive Surgical Inc., Auris Surgical Rbots Inc., and iRobot Corporation.
In April 2023, Apollo Cancer Centres, Navi Mumbai, launched the fourth-generation advanced Da Vinci Xi Robotic System that can be used in the field of oncology, urology, colorectal surgeries, gynecology, thoracic, cardiology, pediatric and gastrointestinal surgeries, kidney transplants and in liver transplantation.
In February 2023, Global Hospital, a Mumbai-based hospital, launched Da Vinci Xi Robotic Surgical System. This robotic surgical system is designed to allow surgeons to perform minimally invasive surgeries precisely and safely. According to the company, this advanced system will be used in various surgical fields, including gynecology, urology, oncology, liver transplantation, cardiology, thoracic, pediatric, and gastrointestinal surgery, to improve patient outcomes and quality of life.